Zynerba’s Failed Cannabidiol Gel Trial Has Upside for Rival GW Pharma

Published: Aug 08, 2017

GW Pharmaceuticals (GWPH) popped to a near five-month high Monday after a rival drug from smaller biotech Zynerba Pharmaceuticals (ZYNE) failed in a midstage trial to treat epilepsy.

In early trading on the stock market today, GW Pharma lifted as much as 4.1% to a high last seen in late March. In recent trades, it was up 1.3%, near 119.20. Zynerba, though, plunged 59% to near 6.20.

Back to news